Kobayashi M, Imai K, Nakai K, Suzuki T, Nagata M, Ito Y, Yamanaka H
Hinyokika Kiyo. 1985 Sep;31(9):1531-7.
Sixty eight patients with renal cell carcinoma were treated at our University in 1968 approximately 1983. The prognosis of these patients was studied retrospectively. Sixty six patients had also been receiving treatment with chemotherapy or radiotherapy except 3 cases after radical nephrectomy. Thirty five of the patients with Stage I approximately N renal cell carcinoma were treated with hormonal therapy using chlormadinone acetate (CMA) or medroxyprogesterone acetate (MPA). CMA was used prophylactically in 21 patients with Stage I approximately IIIA renal cell carcinoma and who had undergone radical nephrectomy. Metastasis was noted in 3 cases in this prophylactic CMA group (21 cases) and 4 cases in the control group (19 cases). No significant difference between these two groups was observed statistically. In the advanced group with Stage IIIC-IV renal cell carcinoma (11 cases), only one case with a complete response was noted after CMA combination therapy.
1968年至1983年期间,我校共治疗了68例肾细胞癌患者。对这些患者的预后进行了回顾性研究。除3例接受根治性肾切除术后的患者外,其余66例患者还接受了化疗或放疗。35例Ⅰ期至N期肾细胞癌患者接受了醋酸氯地孕酮(CMA)或醋酸甲羟孕酮(MPA)的激素治疗。21例Ⅰ期至ⅢA期肾细胞癌且已接受根治性肾切除术的患者预防性使用了CMA。该预防性CMA组(21例)中有3例出现转移,对照组(19例)中有4例出现转移。两组之间在统计学上未观察到显著差异。在晚期ⅢC-IV期肾细胞癌组(11例)中,CMA联合治疗后仅1例完全缓解。